Impacts Treatment Decisions
New research reveals that up to 1 in 61 men with prostate cancer have a genetic mutation that may have caused their cancer. If your patient has metastatic prostate cancer, he may have a hereditary type of prostate cancer and could qualify for additional treatments.
PARP inhibitor therapy is now approved for men with HRR-mutated metastatic prostate cancer. Genetic mutation status is the only way to determine if your metastatic prostate cancer patient is appropriate for these new therapies. The Myriad myRisk® hereditary cancer test was designed to quickly provide accurate results, so you can confidently personalize your patient’s treatment plan.
NCCN Guidelines recommend germline testing for all men with metastatic prostate cancer
No family history is needed for metastatic patients to meet genetic testing guidelines
Testing at diagnosis of metastatic disease can help determine an appropriate treatment plan for your patient
Submit the form below to receive your METS Provider Guide
Confirming your metastatic prostate cancer patients’ genetic mutation status is the only way to determine if new PARP inhibitor therapy is appropriate for them. The Myriad myRisk® hereditary cancer test was designed to quickly provide accurate results, so you can confidently personalize you patients’ treatment plans.
*If for some reason you do not receive the email with your Physician Guide download, please check your junk folder.
With a simple blood or saliva test, Myriad can let you know if your patient is a candidate for additional cancer treatments. We also offer a remote testing option, so your patient can test from the comfort of their own home.
Blood or saliva sample is collected
Sample is sent directly to Myriad
Confidential results delivered to your practice within 1-2 weeks
Cost should never be a barrier when your patients need genetic testing to determine their next treatment. That’s why it’s our promise to make testing accessible and affordable.
Insurers have coverage for hereditary cancer testing
Patients pay $0 for testing at Myriad
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines Nicolosi et al. JAMA Oncol 2019